GTBP · GT Biopharma Inc
United States · RS rating 94 · As of 2026-11-03
| Price | 5.27 USD |
|---|---|
| 1-day change | +2.7% |
| RS rating (overall / 1M / 3M / 12M) | 94 / 28 / 99 / 99 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 34 / 63 / 47 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -9.1% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +54.7% |
| Market cap (USD) | $11.3M |